Advice
References
References
Eli Lilly and Company Limited (2012) Humulin Vials, Cartridges and KwikPens summary of product characteristics [online; accessed 29 July 2013]
European Medicines Agency (2013) European public assessment report: Tresiba
European Medicines Agency (2010) Guideline on missing data in confirmatory clinical trials
Garber AJ, King AB, Del Prato S et al. (2012) Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. The Lancet 379: 1498–507 doi: 10.1016/S0140-6736(12)60205-0
Gough SCL, Bhargava A, Jain R et al. (2013) Low-volume insulin degludec 200 units/mL once daily improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care doi: 10.2337/dc12-2329
Health and Social Care Information Centre (2012) Prescribing for Diabetes in England - 2005-2006 to 2011-2012
Medicines and Healthcare Products Regulatory Agency (April 2013) Insulin degludec (Tresiba▼): available in additional higher strength than existing insulins—care needed to minimise risk of error, including training for patients. Drug Safety Update 6 (issue 9): A1
Meneghini L, Atkin SL, Gough SCL et al. (2013) The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 36: 858–64 doi: 10.2337/dc12-1668
National Institute for Health and Clinical Excellence (2009) Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87
National Institute for Health and Clinical Excellence (2013) Type 2 diabetes mellitus. Key therapeutic topic 12 [online; accessed 29 July 2013]
National Institute for Health and Clinical Excellence (2010) Diabetes – type 2. Clinical Knowledge Summaries [online; accessed 13 August 2013]
National Prescribing Centre (2012) Implementing key therapeutic topics: 3, Type 2 diabetes. MeReC Bulletin [online; accessed 29 July 2013]
Novo Nordisk Limited (2013) Tresiba summaries of product characteristics [online; accessed 29 July 2013]
Novo Nordisk Limited (2012) Insulatard 100 IU/ml, Insulatard Penfill 100 IU/ml, Insulatard InnoLet 100 IU/ml summary of product characteristics [online; accessed 29 July 2013]
Novo Nordisk Limited (2012) Levemir Cartridge 100 U/ml - Penfill, Levemir Pre-filled Pen 100 U/ml - FlexPen and InnoLet summary of product characteristics [online; accessed 29 July 2013]
Philis-Tsimikas A, Del Prato S, Satman I et al. (2013) Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes, Obesity and Metabolism 15: 760–6 doi: 10.1111/dom.12115
Ratner RE, Gough SCL, Mathieu C et al. (2013) Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes, Obesity and Metabolism 15:175–84 doi: 10.1111/dom.12032
Sanofi (2012) Insuman Basal summaries of product characteristics [online; accessed 30 July 2013]
Sanofi (2013) Lantus summaries of product characteristics [online; accessed 30 July 2013]
Tahrani AA, Bailey CJ, Barnett AH (2012) Insulin degludec: a new ultra-longacting insulin. The Lancet 379:1465–7 doi: 10.1016/S0140-6736(12)60527-3
The ORIGIN Trial Investigators (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. The New England Journal of Medicine 367: 319–28 doi: 10.1056/NEJMoa1203858
Zinman B, Philis-Tsimikas A, Cariou B et al. (2012) Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 35: 2464–71 doi: 10.2337/dc12-1205